An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma

The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circumvent multidrug resistance. Previously, we showed...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Fan, Dongmei, Jiang, Linlin, Song, Yuewen, Bao, Shiqi, Yang, Yuanyuan, Yuan, Xiangfei, Zhen, Yongsu, Yang, Ming, Xiong, Dongsheng
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2019
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737009/
https://ncbi.nlm.nih.gov/pubmed/31555598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00861
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky